COMPLETED

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to examine if the use of antioxidant supplements impacts exercise intolerance in people with CF.

Official Title

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Quick Facts

Study Start:2020-02-17
Study Completion:2024-07-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04166396

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of CF
  2. * Men and women (\> 18 yrs. old)
  3. * FEV1 percent predicted \> 40%
  4. * Patients with or without CF related diabetes
  5. * Resting oxygen saturation (room air) \>90%
  6. * Traditional CF-antioxidant medications
  7. * Ability to perform reliable/reproducible PFTs
  8. * Clinically stable for 4 weeks (no exacerbations or need for antibiotic antioxidant within 4 weeks of testing or major change in medical status)
  9. * Pancreatic sufficient and pancreatic insufficient patients
  1. * Children 17 years old and younger
  2. * FEV1\<40% predicted
  3. * Resting O2 saturation \<90%
  4. * Clinical diagnosis of heart disease
  5. * Clinical diagnosis of PAH
  6. * Febrile illness within 4 weeks of a study visit
  7. * Antioxidant for pulmonary exacerbation within 4 weeks of a study visit
  8. * Currently smoking, pregnant or nursing
  9. * Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)
  10. * Patients with B. Cepacia

Contacts and Locations

Principal Investigator

Paula Rodriguez Miguelez, PhD
PRINCIPAL_INVESTIGATOR
Virginia Commonwealth University

Study Locations (Sites)

Virginia Commonwealth University
Richmond, Virginia, 23298
United States

Collaborators and Investigators

Sponsor: Virginia Commonwealth University

  • Paula Rodriguez Miguelez, PhD, PRINCIPAL_INVESTIGATOR, Virginia Commonwealth University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-02-17
Study Completion Date2024-07-30

Study Record Updates

Study Start Date2020-02-17
Study Completion Date2024-07-30

Terms related to this study

Keywords Provided by Researchers

  • resveratrol
  • nicotinamide riboside
  • exercise intolerance

Additional Relevant MeSH Terms

  • Cystic Fibrosis